Wei Zuo
ORCID: 0000-0002-4460-0337Also affiliated with Nanchang University, Harbin Institute of Technology, First Affiliated Hospital of Jiangxi Medical College, Cell Technology (China), Third Affiliated Hospital of Nanchang University, Shanghai East Hospital, Anhui Provincial Children's Hospital, Institute of Geological Sciences, Regend Therapeutics (China), First Affiliated Hospital of Nanchang University
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 2 papers. Top paper: “Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC”.
Lin Wu, Xiangjiao Meng, Yu Yao, Wei Zuo, Wenxiu Yao +29 more
Zili Meng, Ming Liu, Yueqing Zhou, Difei Chen, Yu Zhao +6 more